BIOTECHNOLOGY VALUE FUND L P
CIK 918923 · last filed 2026-04-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.34B
Companies
22
Total Filings
47
Lifetime Open-Market Net
-$1.54B
Filer Profile
Reported Address
44 MONTGOMERY STREET40TH FL
SAN FRANCISCO, CA 94104
Phone
(312) 506-6500
State of Incorporation
DE
Formerly Known As
BIOTECHNOLOGY VALUE FUND L P ET AL (1996–1999)
Related Filers
BVF INC/IL — 513 joint filings, latest 2026-07-16
BVF PARTNERS L P/IL — 513 joint filings, latest 2026-07-16
BIOTECHNOLOGY VALUE FUND II LP — 509 joint filings, latest 2026-07-16
MARK N LAMPERT — 358 joint filings, latest 2026-07-16
BVF INVESTMENTS LLC — 262 joint filings, latest 2017-07-18
BVF Partners OS Ltd. — 237 joint filings, latest 2026-07-16
Biotechnology Value Trading Fund OS LP — 237 joint filings, latest 2026-07-16
BVF GP HOLDINGS LLC — 155 joint filings, latest 2026-07-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MLTX | Director | 8,302,735 | $12.51 | $103.87M | -$1.63B | 2 | 2026-04-02 |
| OLMA | Director | 2,990,983 | $10.22 | $30.57M | $0 | 1 | 2024-12-04 |
| Third Harmonic Bio, Inc. (THRD) Delisted | 1,794,218 | $5.38 | $9.65M | -$143.00M | 1 | 2024-10-31 | |
| KYMR | Director | 294,632 | $114.96 | $33.87M | $1.41M | 3 | 2024-06-28 |
| Repare Therapeutics Inc. (RPTX) Delisted | 10%+ Owner | 548,938 | $2.65 | $1.45M | $203.21M | 2 | 2023-11-17 |
| RAIN | 1,076,314 | $0.74 | $795.4K | $99.26M | 2 | 2021-09-15 | |
| XOMA Royalty Corp (XOMAP) Delisted | 10%+ Owner | 1,960,384 | $24.98 | $48.97M | -$249.99M | 1 | 2021-04-02 |
| Merus N.V. (MRUS) Delisted | 427,377 | $90.00 | $38.46M | $57.50M | 1 | 2021-03-18 | |
| XOMA Royalty Corp (XOMA) Delisted | 10%+ Owner | 171,336 | $40.17 | $6.88M | $15.59M | 3 | 2020-09-23 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 3,078,989 | $38.00 | $117.00M | $14.60M | 1 | 2019-12-26 |
| CYTK | 2,811,818 | $73.77 | $207.43M | $22.60M | 1 | 2019-12-12 | |
| Calithera Biosciences, Inc. (CALA) Delisted | 32,371 | $0.00 | $10 | $44.17M | 1 | 2019-10-31 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 1,167,191 | $0.04 | $52.2K | $47.24M | 3 | 2018-06-21 |
| XENE | 297,464 | $58.65 | $17.45M | $4.07M | 3 | 2017-08-16 | |
| PTN | 122,877 | $11.80 | $1.45M | -$2.14M | 1 | 2014-02-19 | |
| LGND | 3,299,569 | $284.47 | $938.63M | $6.20M | 8 | 2012-12-18 | |
| CAPS | 1,322 | $0.18 | $240 | $338.5K | 2 | 2011-07-28 | |
| FACT | 7,849,140 | $10.72 | $84.14M | $3.64M | 1 | 2010-02-09 | |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 16,062,944 | — | — | -$10.89M | 2 | 2009-12-24 | |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 1,098,392 | $15.50 | $17.03M | -$21.87M | 2 | 2009-08-10 | |
| NBIX | 5,905,447 | $156.22 | $922.55M | $1.80M | 3 | 2009-01-22 | |
| AVIGEN INC \DE (AVGN) Delisted | 8,279,715 | — | — | $584.3K | 1 | 2008-11-20 |
Recent Filings · Page 3 of 5
47 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-08-16 | XENE | Buy (P) | +421,414 | $1.10M | EDGAR |
| 2017-06-29 | XENE | Buy (P) | +598,227 | $2.39M | EDGAR |
| 2017-06-23 | XENE | Buy (P) | +142,877 | $571.5K | EDGAR |
| 2017-01-05 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +30,653 | $41.1K | EDGAR |
| 2016-12-02 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +1,409,758 | $1.67M | EDGAR |
| 2014-02-19 | PTN | Sell (S) | −1,835,796 | -$2.14M | EDGAR |
| 2012-12-18 | LGND | Buy (P) | +32,316 | $602.2K | EDGAR |
| 2012-12-10 | LGND | Buy (P) | +300,600 | $5.39M | EDGAR |
| 2011-10-20 | LGND | Buy (P) | +84,600 | $1.18M | EDGAR |
| 2011-10-14 | LGND | Buy (P) | +452,118 | $6.17M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.